Welcome to Chiesi
USA
Press Releases
June 2025
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of...
05/06/2025
April 2025
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER),...
16/04/2025
January 2025
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting...
29/01/2025
April 2024
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12%...
22/04/2024
March 2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05/03/2024
December 2021
Chiesi Global Rare Diseases Announces Updated U.S. Prescribing Information for FERRIPROX®...
03/12/2021
October 2021
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the...
15/10/2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in...
15/10/2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for...
14/10/2021
September 2021
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Brazil for the...
13/09/2021
June 2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical...
02/06/2021
May 2021
Chiesi USA, Inc. Earns 2021 Life Sciences Award by Triangle Business Journal for second consecutive...
24/05/2021
Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of...
01/05/2021
April 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for...
28/04/2021
February 2021
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying...
26/02/2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from...
23/02/2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of...
10/02/2021
December 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III...
30/12/2020
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for...
23/12/2020
November 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for...
27/11/2020
October 2020
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program...
02/10/2020
September 2020
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for...
17/09/2020
August 2020
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT...
25/08/2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration...
11/08/2020
July 2020
June 2020
May 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License...
28/05/2020
January 2020
